Loading....
The activities of the Let’s Talk Prostate Cancer (LTPC) Expert Group are funded by Astellas Pharma Inc., Agen Inc and Pfizer Inc, which collectively contribute to and support the objectives of the Expert group.
Astellas Pharma Inc. have full and exclusive editorial control over the LTPC Website

Quality of life

Prostate cancer can have a severe impact on those affected and their families.1 This impact manifests itself not only in terms of mortality and survival but also in relation to the daily quality of life (QoL) of patients.2,3 This can include impact on the urinary, sexual and bowel function as well as on energy and performance in physical and social roles.3

Prostate cancer treatment at metastatic phase can have a negative effect on quality of life. Ensuring early detection and diagnosis is therefore vital for enabling those affected to live with a better quality of life.4

A patient survey carried out by Europa Uomo provides a snapshot of the impact on quality of life for men with prostate cancer across Europe.5

The survey shows that urinary incontinence and sexual dysfunction were the two areas where men reported the lowest quality of life scores.5

The results indicate that the best quality of life scores are seen where the cancer is discovered at an early stage.5 Efforts should therefore be made to ensure early detection and awareness to avoid unnecessary deterioration in quality of life.

To access the complete survey results, please access Europa Uomo’s presentation here.

A presentation detailing the main findings of the survey is also available to download in several languages:

EUPROMS English
EUPROMS Czech
EUPROMS Danish
EUPROMS Dutch
EUPROMS Finnish
EUPROMS French
EUPROMS German
EUPROMS Greek
EUPROMS Hungarian
EUPROMS Italian
EUPROMS Latvian
EUPROMS Lithuanian
EUPROMS Norwegian
EUPROMS Polish
EUPROMS Portuguese
EUPROMS Spanish
EUPROMS Swedish

References

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Orchid. More to do, Identifying and tackling the unmet need in prostate cancer care. 2015. Accessible at https://orchid-cancer.org.uk/wpcontent/uploads/2016/02/Prostate-Cancer-More-to-do-Report-FINAL.pdf (last accessed March 2022)

2 Ferlay, J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer. 2018; 103:356-387

3 Eton, DT. Prostate Cancer and health-related Quality of Life. 2008. Accessible at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2593110/pdf/nihms-79523.pdf (last accessed March 2022)

4 Van Poppel, H et al. Policy Paper on PSA Screening for Prostate Cancer: Has the time come to reconsider structured population-based PSA screening for prostate cancer? 2019. Accessible at http://epad.uroweb.org/wp-content/uploads/EAU_policy-briefing_PSA.pdf (last accessed March 2022)

5 Europa Uomo. The real effects of prostate cancer treatment: EUPROMS First ever prostate patient-driven quality of life study. 2020. Accessible at https://www.europa-uomo.org/news/quality-of-life-worse-than-previously-thought-europa-uomo-reports/ (last accessed March 2022)